摘要
目的探讨血清半胱氨酸蛋白酶抑制剂S(CST4)在胃肠癌中的临床意义。方法利用血清CST4试剂盒(ELISA法)和化学发光法分别检测80例胃肠癌病人(胃癌40例,结直肠癌40例)和40例正常人对照血清CST4、CEA、CA19-9和CA125浓度,并对检测结果进行统计分析,评估CST4的临床意义。结果胃肠癌组CST4浓度中位数分别为78.272(36.892,188.395)U/L和66.265(39.751,108.890)U/L,均显著高于正常对照组中位数30.920(16.055,56.995)U/L,差异有统计学意义(P<0.05)。胃肠癌患者CST4的ROC曲线下面积(AUC)(分别为0.755、0.754)、胃肠癌早期(一期和二期)CST4的阳性检出率(均为26.9%)和检测灵敏度、特异性、阳性似然比(PLR)、阴性似然比(NLR)、阳性预测值(PPV)和阴性预测值(NNV)等检测指标均优于CEA、CA19-9和CA125。胃肠癌Ⅲ+Ⅳ期患者CST4中位数水平分别为165.653(58.767,334.933)U/L和74.365(41.192,183.306)U/L,均高于胃肠癌Ⅰ期和Ⅱ期患者,胃癌组水平差异有统计学意义(P<0.05)。结论胃肠癌组血清CST4水平显著高于正常对照组,早期阳性检出率和诊断性能优于传统肿瘤标志物,并且与肿瘤预后相关,有望成为新的胃肠癌早期肿瘤标志物。
Objective To explore the clinical applications of cystatin S(CST4)in gastrointestinal cancers.Methods A total of 80 serum samples from gastrointestinal cancer patients[including 40 gastric cancer(GC)and 40 colorectal cancer(CRC)]and 40 serum samples from healthy controls were all detected by human CST4 detective kit(ELISA)and CEA,CA19-9 and CA125 kits(CLA),then Statistical analysis were made to evaluate the clinical values of CST4 in gastrointestinal cancers.Results The median concentrations of CST4 in GC group and CRC group[78.272(36.892,188.395)U/L and 66.265(39.751,108.890)U/L respectively]are significantly higher than those of normal controls[30.920(16.055,56.995)U/L](P<0.05).The area under the ROC curve(AUC)of CST4 for GC and CRC(0.755 and 0.754 respectively),the positive detection rate in the early stages(stage I and II)of GC and CRC(both 26.9%)and the diagnostic sensitivity,specificity,positive likelihood ratio(PLR),negative likelihood ratio(NLR),positive predictive value(PPV)and negative predictive value(NNV)of CST4 are all superior to CEA,CA19-9 and CA125.The median concentrations of CST4 in stagesⅢ+Ⅳof GC and CRC group[165.653(58.767,334.933)U/L and 74.365(41.192,183.306)U/L respectively]are both higher than those of stageⅠand stageⅡ,and the difference of GC group is statistically significant as well(P<0.05).Conclusions The median concentrations of CST4 in gastrointestinal cancer patients’serum are significantly higher than those of normal controls,and the positive detection rate in the early stages and the diagnostic values of CST4 are superior to traditional biomarkers,and concentrations of CST4 are related to the cancer prognosis,reveals that CST4 may be a new early novel biomarker of gastrointestinal cancers.
作者
周爱群
张志勇
方全钢
曾黎峰
刘燕鸣
孔维莉
ZHOU Aiqun;ZHANG Zhiyong;FANG Quangang(Jiangxi Provincial People’s Hospital,The First AFfiliation Hospital of Nanchang Medical Colleye,Jiangxi Nanchang,330006,China)
出处
《实验与检验医学》
CAS
2023年第4期383-387,共5页
Experimental and Laboratory Medicine
基金
江西省卫生健康委科技计划,编号20190777。
